EOS imaging Installs System at Prominent Private Clinic in Switzerland
February 18 2015 - 1:12PM
Business Wire
Clinique de la Source in Lausanne adopts EOS®
for its top-rated orthopedic care
Regulatory News:
EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in
orthopedic 2D/3D imaging, today announced the installation of the
EOS® system at the Clinique de la Source in Lausanne, Switzerland
marking the sixth EOS installation in the country and the first in
a private healthcare center in the Vaud canton.
Clinique de la Source, a member of the Swiss Leading Hospitals
organization, is globally recognized in orthopedic surgery and
treats more than 100,000 patients each year. The Institute of
Radiology at La Source is the largest private medical imaging
center in the Vaud region of Switzerland where Lausanne is located.
As such, this clinic features cutting-edge radiological imaging
equipment - now including the gold standard in low-dose
stereoradiographic imaging with the EOS® system.
"Ensuring patient comfort, limiting radiation exposure and
ensuring that our imaging offerings are cost-effective for both
patients and the Swiss healthcare system are major priorities for
the entire La Source team, from radiologists to hospital
leadership," said Sylvain Duc, Radiologist at La Source's Institute
of Radiology. "The addition of the low-dose EOS imaging system and
the enhanced 2D and 3D images it will produce to our already robust
imaging offerings will only strengthen the patient care at La
Source."
Marie Meynadier, CEO of EOS imaging, said, “The quality of care
in orthopedic surgery at La Source led to their decision to adopt
EOS® for their diagnosis, planning and control imaging. We are very
pleased by that decision from a leading institution, which
contributes to turning EOS into a standard of care on the Swiss
market.”
The EOS® system provides full-body stereoradiographic images of
patients in functional positions, in both 2D and 3D. EOS exams
require a radiation dose 50% to 85% less than Digital Radiology and
95% less than basic CT scans. The new EOS Micro Dose option,
recently cleared by the Food and Drug Administration, allows a
further drastic step towards the ALARA principle (As Low As
Reasonably Available) by bringing pediatric spine follow up exams
at the dose level equivalent to a week of natural background
radiation on Earth.
For further information about the Company or EOS®, the first
full body, low dose 2D/3D imaging system, please visit
http://www.eos-imaging.com/.
EOS imaging has been chosen to be included in the new
EnterNext© PEA-PME 150 index, composed of 150 French companies and
listed on Euronext and Alternext markets in Paris.
EOS imaging is listed on Compartment C of Euronext ParisISIN:
FR0011191766 – Ticker: EOSI
Next press release: annual results for 2014 and turnover for the
1st quarter of 2015: on April 20, 2015 (after market).
About EOS imaging:
EOS imaging designs, develops, and markets EOS®, an innovative
medical imaging system based on technology that enabled George
Charpak to win the Nobel Prize for Physics, as well as associated
solutions. The Company is authorized to market in 47 countries,
including the United States (FDA), Japan and the European Union
(EU). As of December 31, 2014 the Group posted 2014 consolidated
revenue of €20.1 million and employed 107 people including an
R&D team of 39 engineers. The Group is based in Paris and holds
four subsidiaries in Besançon (France), Cambridge (Massachusetts),
Montreal (Canada) and Frankfurt (Germany), and offices in
Singapore.
Anne RenevotCFOPh: +33 (0)1 55 25 61
24investors@eos-imaging.comorNewCapFinancial communication
and investor relationsSophie Boulila / Pierre LaurentPh: +33 (0)1
44 71 94 91 - eosimaging@newcap.frorThe Ruth Group (US)Press
relations / Calvin AllenPh: 646-536-7002callen@theruthgroup.com
Eos (CE) (USOTC:EOSI)
Historical Stock Chart
From Apr 2024 to May 2024
Eos (CE) (USOTC:EOSI)
Historical Stock Chart
From May 2023 to May 2024
